Genentech initiates study on cevostamab and elranatamab for relapsed/refractory multiple myeloma
Genentech is evaluating the safety and pharmacokinetics of cevostamab in combination with elranatamab for R/R MM.
Asset / Drug
Drug and asset intelligence for cevostamab with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.